Pediatric inflammatory bowel disease patients from vulnerable areas have delayed remission and more hospitalizations
Journal of Pediatric Gastroenterology and Nutrition · 2026-02 · 82 (2) · 447-453
DOI: 10.1002/jpn3.70271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 18.11.2025. Verfasst von Bradley Anding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Hospitalization, Social Determinants of Health, Inflammatory Bowel Diseases, Vulnerable Populations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objectives
Pediatric inflammatory bowel disease (IBD) has a rising incidence. While the underlying etiology is not fully understood, genetics and environmental factors are known to play a role. Social determinants of health (SDoH) also play a role in worsening morbidity and mortality for chronic diseases. This study evaluated the association between SDoH and pediatric IBD, hypothesizing that individuals residing in more socially vulnerable areas will have worse outcomes during the first year of diagnosis.
Methods
This retrospective cohort study included 222 patients diagnosed with IBD at Children's of Alabama from 2018 to 2022. The social vulnerability index (SVI) was used to quantify neighborhood‐level socioeconomic vulnerability. Primary outcomes were hospitalization at diagnosis, hospitalization during the first year, disease activity at 6 months, and persistent disease activity at 1 year.
Results
Patients from neighborhoods in the most socioeconomically vulnerable quartile (top 25% of SVI) were more likely to be hospitalized at diagnosis (adjusted odds ratio [aOR] 2.51, p = 0.028), more likely to be hospitalized during the first year (aOR 3.44, p = 0.031), and more likely to have active disease at 6 months (unadjusted OR 2.47, p = 0.016) compared to those from neighborhoods in the least vulnerable quartile. However, there were no significant differences by neighborhood socioeconomic vulnerability in active disease at 1 year.
Conclusion
Social vulnerability contributes to increased risk of hospitalization and delays in achieving remission during the first year after new diagnosis of IBD. This finding highlights the importance of SDoH screening to identify at‐risk patients at the time of diagnosis to guide targeted interventions and prevent worse disease outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Anesthesiology and Perioperative Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Bradley Anding
Förderung
- None
Zitieren
APA
Anding, B., Baker, E., Oates, G. R., & Jester, T. (2026). Pediatric inflammatory bowel disease patients from vulnerable areas have delayed remission and more hospitalizations. Journal of Pediatric Gastroenterology and Nutrition, 82(2), 447-453. https://doi.org/10.1002/jpn3.70271
Vancouver
Anding B, Baker E, Oates GR, Jester T. Pediatric inflammatory bowel disease patients from vulnerable areas have delayed remission and more hospitalizations. Journal of Pediatric Gastroenterology and Nutrition. 2026;82(2):447-453. doi:10.1002/jpn3.70271
BibTeX
@article{Anding2026,
author = {Anding, Bradley and Baker, Elizabeth and Oates, Gabriela R and Jester, Traci},
title = {Pediatric inflammatory bowel disease patients from vulnerable areas have delayed remission and more hospitalizations},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
volume = {82},
number = {2},
pages = {447--453},
doi = {10.1002/jpn3.70271}
}
EUVIMED